Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00424021




Registration number
NCT00424021
Ethics application status
Date submitted
17/01/2007
Date registered
18/01/2007
Date last updated
27/01/2012

Titles & IDs
Public title
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
Scientific title
An Open-Label, Long-Term Study of Ambrisentan in Pulmonary Hypertension Subjects Having Completed Myogen Study AMB-220
Secondary ID [1] 0 0
AMB-220-E
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ambrisentan

Treatment: Drugs: ambrisentan
1, 2.5, 5, and 10 mg ambrisentan given orally once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Pulmonary Arterial Hypertension (PAH) Who Completed the Phase II NCT00046319 Study and Who Experienced Severe Adverse Events (AEs) During Long-term Ambrisentan Exposure
Timepoint [1] 0 0
Week 24 (AMB-220-E baseline) to Week 334
Primary outcome [2] 0 0
Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Moderate Severity During Long-term Ambrisentan Exposure
Timepoint [2] 0 0
Week 24 (AMB-220-E baseline) to Week 329.3
Primary outcome [3] 0 0
Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Mild Severity During Long-term Ambrisentan Exposure
Timepoint [3] 0 0
Week 24 (AMB-220-E baseline) to Week 329.3
Secondary outcome [1] 0 0
Baseline Measurement in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Distance (Baseline [Week 24])
Timepoint [1] 0 0
Week 24 (AMB-220-E baseline)
Secondary outcome [2] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Distance (Last Observation Carried Forward [LOCF]) (Week 48)
Timepoint [2] 0 0
24 weeks (Week 24 to Week 48)
Secondary outcome [3] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Distance (LOCF) (Week 108)
Timepoint [3] 0 0
84 weeks (Week 24 to Week 108)
Secondary outcome [4] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Distance (LOCF) (Week 156)
Timepoint [4] 0 0
132 weeks (Week 24 to Week 156)
Secondary outcome [5] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Distance (LOCF) (Week 204)
Timepoint [5] 0 0
180 weeks (Week 24 to Week 204)
Secondary outcome [6] 0 0
Baseline Measurement in Exercise Capacity as Measured by the Borg Dyspnea Index (BDI) (Baseline [Week 24])
Timepoint [6] 0 0
Week 24 (AMB-220-E baseline)
Secondary outcome [7] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 48)
Timepoint [7] 0 0
24 weeks (Week 24 to Week 48)
Secondary outcome [8] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 108)
Timepoint [8] 0 0
84 weeks (Week 24 to Week 108)
Secondary outcome [9] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 156)
Timepoint [9] 0 0
132 weeks (Week 24 to Week 156)
Secondary outcome [10] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the BDI (LOCF) (Week 204)
Timepoint [10] 0 0
180 weeks (Week 24 to Week 204)
Secondary outcome [11] 0 0
Baseline Measurement in Exercise Capacity as Measured by the World Health Organization (WHO) Functional Classification (Baseline [Week 24])
Timepoint [11] 0 0
Week 24 (AMB-220-E baseline)
Secondary outcome [12] 0 0
Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 24 Weeks of Treatment in AMB-220-E
Timepoint [12] 0 0
24 weeks (Week 24 [baseline of AMB-220-E] to Week 48)
Secondary outcome [13] 0 0
Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 84 Weeks of Treatment in AMB-220-E
Timepoint [13] 0 0
84 weeks (Week 24 of NCT00046319 to Week 108)
Secondary outcome [14] 0 0
Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 132 Weeks of Treatment in AMB-220-E
Timepoint [14] 0 0
132 weeks (Week 24 of NCT00046319 to Week 156)
Secondary outcome [15] 0 0
Exercise Capacity as Measured by the WHO Functional Classification (LOCF) After 180 Weeks of Treatment in AMB-220-E
Timepoint [15] 0 0
180 weeks (Week 24 of NCT00046319 to Week 204)
Secondary outcome [16] 0 0
Baseline Measurement in Exercise Capacity as Measured by the Subject Global Assessment (SGA) (Baseline [Week 24])
Timepoint [16] 0 0
Week 24 (AMB-220-E baseline)
Secondary outcome [17] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the SGA (LOCF) (Week 48)
Timepoint [17] 0 0
24 weeks (Week 24 to Week 48)
Secondary outcome [18] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the SGA (LOCF) (Week 108)
Timepoint [18] 0 0
84 weeks (Week 24 to Week 108)
Secondary outcome [19] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the SGA (LOCF) (Week 156)
Timepoint [19] 0 0
132 weeks (Week 24 to Week 156)
Secondary outcome [20] 0 0
Change From Baseline (Week 24 of NCT00046319) in Exercise Capacity as Measured by the SGA (LOCF) (Week 204)
Timepoint [20] 0 0
180 weeks (Week 24 to Week 204)
Secondary outcome [21] 0 0
Time to Clinical Worsening of PAH
Timepoint [21] 0 0
Week 0 (NCT00046319 baseline) to Week 360
Secondary outcome [22] 0 0
Failure-free Treatment Status
Timepoint [22] 0 0
Week 0 (NCT00046319 baseline) to Week 360
Secondary outcome [23] 0 0
Long-term Survival
Timepoint [23] 0 0
Week 24 (AMB-220-E baseline) to Week 329.3

Eligibility
Key inclusion criteria
* Must have completed Visit 14/Week 24 of the NCT00046319 study.
* Women of childbearing potential must have a negative urine pregnancy test at the Screening/Enrollment Visit and agree to use a reliable double barrier method of contraception until study completion and for >=4 weeks following their final study visit.
* Must have completed the Down-titration Period of NCT00046319 prior to enrollment in AMB-220-E and will meet the following additional criteria:
* Subjects with a diagnosis of HIV must have stable disease status at the time of Screening/Enrollment.
* Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening Visit.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Chronic prostanoid therapy, or other investigational prostacyclin derivative within 4 weeks prior to the Screening Visit.
* Intravenous inotrope use within 2 weeks prior to the Screening Visit.
* Females who are pregnant or breastfeeding.
* Contraindication to treatment with an endothelin receptor antagonist (ERA).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2009
Sample size
Target
Accrual to date
Final
54
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00424021